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What\'s new?Glycaemic control can be assessed with HbA~1c~ or with descriptive statistics from continuous glucose monitoring (CGM) data. HbA~1c~ is highly correlated with the average CGM‐derived glucose value.Using HbA~1c~ and CGM data from recently completed clinical trials, we found HbA~1c~ to be highly correlated with the percentage of CGM values indicating hyperglycaemia, but poorly correlated with the percentage of CGM values indicating hypoglycaemia.Because CGM data revealed hypoglycaemia among participants with HbA~1c~ values ≥69 mmol/mol (≥8.5%), relaxation of HbA~1c~ goals is not an effective strategy for hypoglycaemia prevention.CGM‐based heuristics to guide therapy intensification efforts independently of HbA~1c~ are also described.

Introduction {#dme14065-sec-0007}
============

HbA~1c~ is a valuable indirect biomarker of average glycaemia, and informs the relationship between glycaemic control and the chronic vascular complications of diabetes [1](#dme14065-bib-0001){ref-type="ref"}; however, inter‐individual variations in the ratio between mean glucose and HbA~1c~ [2](#dme14065-bib-0002){ref-type="ref"}, combined with the insensitivity of HbA~1c~ to the timing, amplitude, and frequency of glucose concentration swings [3](#dme14065-bib-0003){ref-type="ref"}, limit the precision with which it can be used to guide therapy intensification efforts. By contrast, continuous glucose monitoring (CGM) allows the direct and nearly instantaneous assessment of mean glucose concentrations and the glycaemic responses to interventions; as such, it can empower and motivate people with diabetes [4](#dme14065-bib-0004){ref-type="ref"} and help to improve glycaemic control [5](#dme14065-bib-0005){ref-type="ref"}. The recently described glucose management indicator is a linear function of CGM‐derived mean glucose values and is intended to reduce potential confusion by supplanting the earlier 'estimated HbA~1c~' metric [6](#dme14065-bib-0006){ref-type="ref"}. Other metrics for characterization of short‐term glycaemic control with CGM data were proposed by an international consensus conference [7](#dme14065-bib-0007){ref-type="ref"} and include time in range (TIR; usually expressed as the percentage of glucose values from 3.9 to 10.0 mmol/l), as well as the time spent above or below various thresholds indicating clinically significant or immediately actionable hypoglycaemia or hyperglycaemia. In the present study, we report on the relationship between CGM‐derived glycaemic variables and the corresponding HbA~1c~ levels by analysing individual‐level data from recently completed randomized clinical trials.

Participants and methods {#dme14065-sec-0008}
========================

Four recently completed randomized controlled studies of adults with diabetes provided data for the present study. Phase I of the DIAMOND study enrolled participants with Type 1 diabetes [8](#dme14065-bib-0008){ref-type="ref"} or participants with Type 2 diabetes [9](#dme14065-bib-0009){ref-type="ref"} using multiple daily injections of insulin, and compared the effects of CGM to those of usual care based on self‐monitoring of blood glucose. Phase II of the DIAMOND study enrolled participants with Type 1 diabetes who had completed the CGM arm in phase I. All continued with CGM; they were randomized to either continue on multiple daily injections or to switch to insulin pump therapy [10](#dme14065-bib-0010){ref-type="ref"}. The REPLACE‐BG study [11](#dme14065-bib-0011){ref-type="ref"} enrolled participants with well‐controlled Type 1 diabetes and compared the safety and efficacy of CGM used as an adjunct to self‐monitoring of blood glucose to that of CGM used non‐adjunctively for therapeutic decisions. The HypoDE study [12](#dme14065-bib-0012){ref-type="ref"} enrolled participants with Type 1 diabetes and a history of impaired hypoglycaemia awareness or severe hypoglycaemia, and studied the effectiveness of real‐time CGM for reducing the number of hypoglycaemic events. All of these studies lasted at least 24 weeks and used current or recent‐generation CGM systems (G4 Platinum or G5 Mobile; Dexcom, Inc., San Diego, CA, USA). The DIAMOND and REPLACE‐BG studies excluded participants with evidence of decreased renal function (estimated glomerular filtration rate (GFR) of \<45 or \<30 ml/min in the respective studies); the DIAMOND study also excluded participants with conditions affecting the reliability of HbA~1c~ measurements. Data from participants for whom \<2 weeks of CGM data were available were excluded. Baseline characteristics of participants in the four studies and the number of participants from each study whose data were used in the present analysis are given in Table [1](#dme14065-tbl-0001){ref-type="table"}.

###### 

Baseline characteristics of participants

  Study                      DIAMOND phase I   DIAMOND phase II   REPLACE‐BG   HypoDE                        
  -------------------------- ----------------- ------------------ ------------ --------- --------- --------- ---------
  Assigned to CGM, *n*       105               37                 38           149       77        74        75
  Age, years                 46±14             46±15              45±12        44±14     45±13     47±12     46±12
  Diabetes duration, years   19 (9--29)        22 (12--29)        15 (6--29)   23±12     25±12     22±14     21±14
  HbA~1c~, mmol/mol          70±7.7            60±7.7             60±9.8       54±7.7    53±7.7    57±10.6   59±10.9
  HbA~1c~, %                 8.6±0.7           7.6±0.7            7.6±0.9      7.1±0.7   7.0±0.7   7.3±1.0   7.6±1.0
  Analysed, *n*              104               69                 216          141                           

Values are reported as mean ± [sd]{.smallcaps} or median (interquartile range).
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End‐of‐study HbA~1c~ values and corresponding CGM metrics from the last 3 months of study participation were available from 104 completers of the DIAMOND phase I study (29 with Type 1 diabetes who did not continue to phase II and 75 with Type 2 diabetes who were not eligible for phase II), from 69 completers of the DIAMOND phase II study, from 216 completers of the REPLACE‐BG study, and from 141 completers of the HypoDE study. For the DIAMOND and REPLACE‐BG studies, HbA~1c~ values were determined at Northwest Lipid Research Laboratories, Seattle, with the DCCT standardized analyser (Tosoh Bioscience, South San Francisco, CA, USA). For the HypoDE study, HbA~1c~ values were determined with a certified high‐performance liquid chromatography method at MLM Medical Laboratories (Mönchengladbach, Germany).

The variable TIR is expressed as a percentage of glucose values in the range 3.9--10.0 mmol/l. Hyperglycaemic exposure is expressed as the percentage of glucose values \> 13.9 mmol/l, while hypoglycaemic exposure is expressed as the percentage of glucose values below either 3.9 mmol/l or 3.0 mmol/l. Participants were categorized based on end‐of‐study HbA~1c~ levels ranging from \<48 mmol/mol (\<6.5%) to ≥69 mmol/mol (≥8.5%), and separately into categories based on CGM‐derived metrics.

Results {#dme14065-sec-0009}
=======

Among the 530 participants, the median number of reported glucose values was 8567, equivalent to 29.7 complete days of data per participant, assuming that points were collected at 5‐min intervals. The mean (±[sd]{.smallcaps}; range) HbA~1c~ value was 56 (±9; 33--98) mmol/mol \[7.3 (±0.8; 5.2--11.1)%\]. The mean (±[sd]{.smallcaps}; range) glucose value was 9.3 (±1.5; 5.2--16.2) mmol/l. The average glucose value was highly correlated with both TIR (*r*=--0.93) and percentage of glucose values \>13.9 mmol/l (*r*=0.92). Higher levels of glycaemic variability (measured as the standard deviation of glucose values) were associated with higher mean glucose values (*r*=0.66) and lower TIR values (*r*=--0.76).

Relationships between HbA~1c~ and four CGM‐based glycaemic variables are shown in Fig. [1](#dme14065-fig-0001){ref-type="fig"}. There was a strong inverse correlation between HbA~1c~ and TIR, such that every 10% change in TIR was associated with a 7mmol/mol (0.7%) change in HbA~1c~. There were strong positive correlations between HbA~1c~ and both mean glucose and the percentage of glucose values \>13.9 mmol/l, and a weak inverse correlation between HbA~1c~ and the percentage of glucose values \<3.9 mmol/l. Of the 139 individuals with a TIR of ≥70%, 130 had a glucose management indicator of ≤7% and 111 had an HbA~1c~ of ≤53 mmol/mol (7%).

![Relationships between HbA~1c~ and (a) time in range (TIR), (b) mean glucose, (c) percentage of glucose values \>13.9 mmol/l and (d) percentage of glucose values \<3.9 mmol/l.](DME-36-1637-g001){#dme14065-fig-0001}

The median and interdecile (10^th^ to 90^th^ percentile) ranges of CGM‐derived variables for participants in six different HbA~1c~‐based groups are shown in Fig. [2](#dme14065-fig-0002){ref-type="fig"}. For the 76 participants with HbA~1c~ values \<48 mmol/mol (\<6.5%), the median TIR was 74.9%. In this group, the median frequency of glucose values \<3.9 mmol/l was 5.6% and the median frequency of glucose values \>13.9 mmol/l was 2.5%. For the 188 participants with HbA~1c~ values ≤53 mmol/mol (≤7.0%), the median TIR was 72.1%, with 90% of participants having a TIR of \>57%. This group of participants with relatively good glycaemic control had a mean glucose level of 8.0 mmol/l, median percentage of glucose values \<3.9 mmol/l of 4.4%, and a median percentage of glucose values \>13.9 mmol/l of 3.7%. For the 42 participants with HbA~1c~ values ≥69 mmol/mol (≥8.5%), the median TIR was 35.5%. In this group, the median frequency of glucose values \<3.9 mmol/l was 1.1%, and the median frequency of glucose values \>13.9 mmol/l was 27.8%. Overall, the median percentage of glucose values \<3.0 mmol/l was \<1.2% (\<20 min/day), but the median percentage of glucose values \>13.9 mmol/l ranged from 2.5% (0.6 h/day) to 27.8% (6.7 h/day) in groups with the lowest to the highest HbA~1c~ values, respectively. For participants with HbA~1c~ values ≥64 mmol/mol (≥8.0%), the median TIR was 43.8%, with 90% of participants having a TIR of \<59%.

![Median and interdecile ranges of various continuous glucose monitoring (CGM)‐derived variables for participants with HbA~1c~ values in different bins.](DME-36-1637-g002){#dme14065-fig-0002}

Median and interdecile ranges of HbA~1c~ values for participants grouped according to various CGM‐derived metrics are shown in Fig. [3](#dme14065-fig-0003){ref-type="fig"}. At least 90% of the individuals in several CGM‐based groups had HbA~1c~ values ≤53 mmol/mol (≤7.0%), including groups with mean glucose values \<7.8 mmol/l, with TIR values of \> 80%, and \<2% of glucose values \>13.9 mmol/l. By contrast, \>90% of the individuals in other CGM‐based groups had HbA~1c~ values \>53 mmol/mol (\>7.0%), including groups with mean glucose values \>10.0 mmol/l, with TIR values of \<50%, and with ≥16% of glucose values \>13.9 mmol/l. Of the 113 individuals with HbA~1c~ values ≥64 mmol/mol (≥8.0%), only nine (8%) had TIR values of ≥60%, and 57 (50%) had 20% or more of their glucose values \>13.9 mmol/l. By contrast, of the 188 individuals with HbA~1c~ values ≤53 mmol/mol (≤7.0%), 159 (85%) had TIR values of ≥60%, and only two (1%) had ≥20% of their glucose values \>13.9 mmol/l.

![Median and interdecile ranges of HbA~1c~ values for participants with various continuous glucose monitoring (CGM)‐derived variables in different bins.](DME-36-1637-g003){#dme14065-fig-0003}

These relationships were considered separately for individuals with Type 1 diabetes and those with Type 2 diabetes (*n*=455 and *n*=75, respectively). Although all participants with Type 2 diabetes were on intensive insulin therapy, they experienced less hypoglycaemia than participants with Type 1 diabetes at both the 3.9 mmol/l threshold (1.2% vs 4.1%) and the 3.0 mmol/l threshold (0.3% vs 1.3%).

Discussion {#dme14065-sec-0010}
==========

The present analysis adds detail to the close relationship that has been observed between several CGM‐derived glycaemic variables and HbA~1c~, with an especially strong correlation between HbA~1c~ and mean glucose (and the glucose management indicator, which is derived from the mean glucose). HbA~1c~ was strongly related to hyperglycaemic exposure and inversely related to TIR. The correlations between HbA~1c~ and hypoglycaemic exposure were inverse and relatively weak, consistent with the insensitivity of HbA~1c~ to hypoglycaemic events. The present analysis also provides clinicians with heuristics for guiding therapy intensification efforts, such as the value of minimizing the percentage of glucose values \>13.9 mmol/l and helping define optimal TIR goals. Consistent with earlier observations from the T1D Exchange registry regarding severe hypoglycaemia in people with poor glycaemic control [13](#dme14065-bib-0013){ref-type="ref"}, [14](#dme14065-bib-0014){ref-type="ref"}, glucose values \<3.0 mmol/l were recorded in individuals with HbA~1c~ levels ≥69 mmol/mol (≥8.5%), showing that relaxing HbA~1c~ goals is an ineffective strategy for hypoglycaemia prevention. The range of mean glucose values for specific HbA~1c~ values, and the range of HbA~1c~ values for specific mean glucose values, confirm and extend earlier observations of individual variation in glycation ratios [2](#dme14065-bib-0002){ref-type="ref"}, [3](#dme14065-bib-0003){ref-type="ref"} and justify incorporating CGM‐derived metrics into routine care discussions.

Strengths of the present study include the fact that the four clinical trials providing data for this analysis addressed different questions, enrolled adults with either Type 1 or Type 2 diabetes, and observed a wide range of end‐of‐study HbA~1c~ values. The comparability of CGM systems and the central laboratory measurements of HbA~1c~ levels were additional strengths of the present study. The choice to analyse participants with at least 14 days of CGM data was justified by separate studies [15](#dme14065-bib-0015){ref-type="ref"}, [16](#dme14065-bib-0016){ref-type="ref"} showing that this amount of data provides a good estimate of glucose metrics for a 3‐month period; however, most participants evaluated in the present study provided more than twice this amount.

Our results are consistent with those reported in the study by Vigersky and McMahon [17](#dme14065-bib-0017){ref-type="ref"} regarding the relationship between HbA~1c~ and TIR, in which the two were highly correlated (*r*=0.84) and each 10% change in TIR was associated with a 9mmol/mol (0.8%) change in HbA~1c~. A recent report on children and adolescents in Sweden [18](#dme14065-bib-0018){ref-type="ref"} noted similar relationships between HbA~1c~ and CGM‐derived metrics such as TIR and time spent in the narrower target range of 3.9--7.8 mmol/l, and suggested that participants aged 6--18 years should aim to keep their time in this range at or above 50%.

These results confirm prior studies showing that people with similar HbA~1c~ levels may have widely disparate exposure to hypoglycaemia and hyperglycaemia, and emphasize the value of CGM studies when evaluating people with diabetes. CGM‐derived outcomes such as TIR are increasingly recognized as drivers of improved diabetes management and mindset [19](#dme14065-bib-0019){ref-type="ref"}, and CGM‐based estimates of hypoglycaemia and hyperglycaemia can be very meaningful and feasible outcome measures for clinical trials [20](#dme14065-bib-0020){ref-type="ref"}. CGM data can also help manage people with impaired renal function, haemoglobinopathies, or other conditions in which HbA~1c~ levels might be misleading. When using CGM reports to inform therapy intensification strategies in people with suboptimally controlled diabetes, clinicians may wish to focus on strategies to increase TIR and limit the duration of hyperglycaemic excursions.
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